Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $38.00 Consensus Target Price from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been assigned a consensus rating of “Buy” from the five analysts that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $38.80.

Several research analysts have weighed in on KNSA shares. Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, April 29th. Finally, Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective for the company.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA opened at $26.95 on Friday. The firm has a 50-day simple moving average of $22.07 and a 200-day simple moving average of $21.34. Kiniksa Pharmaceuticals has a fifty-two week low of $17.38 and a fifty-two week high of $28.56. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -192.51 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $137.79 million during the quarter, compared to analysts’ expectations of $128.35 million. During the same period in the prior year, the company posted ($0.25) earnings per share. The firm’s revenue for the quarter was up 72.5% on a year-over-year basis. Equities research analysts forecast that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Insider Buying and Selling

In other news, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the transaction, the chief operating officer now directly owns 81,975 shares in the company, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Ross Moat sold 18,259 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $20.29, for a total value of $370,475.11. Following the sale, the insider now owns 9,415 shares in the company, valued at $191,030.35. The trade was a 65.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 224,820 shares of company stock valued at $5,386,361 in the last quarter. Company insiders own 54.57% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. GAMMA Investing LLC boosted its position in Kiniksa Pharmaceuticals by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after acquiring an additional 568 shares during the period. Asset Management One Co. Ltd. acquired a new stake in Kiniksa Pharmaceuticals in the first quarter worth about $41,000. Wealthquest Corp bought a new position in Kiniksa Pharmaceuticals in the 1st quarter valued at about $42,000. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals during the 4th quarter valued at about $61,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Kiniksa Pharmaceuticals during the 4th quarter worth about $158,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.